Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ718MR)

This product GTTS-WQ718MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ718MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10183MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ2052MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ12444MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ15814MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ11946MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ14800MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ3604MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ10638MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW